Nurix Therapeutics, Inc. (NRIX) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $23.30 (-1.19%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 29, 2026 | Derek Archila | Wells Fargo | $29.00 | +24.5% |
| Dec 10, 2025 | Robert Burns | H.C. Wainwright | $31.00 | +33.0% |
| Oct 22, 2025 | Gregory Renza | RBC Capital | $29.00 | +24.5% |
| Oct 10, 2025 | Matthew Biegler | Oppenheimer | $28.00 | +20.2% |
| Jul 15, 2025 | Terence Flynn | Morgan Stanley | $16.00 | -31.3% |
| Jul 10, 2025 | Matthew Biegler | Oppenheimer | $30.00 | +28.8% |
| Feb 3, 2025 | Terence Flynn | Morgan Stanley | $17.00 | -27.0% |
| Dec 5, 2024 | Etzer Darout | BMO Capital | $35.00 | +50.2% |
| Oct 24, 2024 | David Dai | UBS | $35.00 | +50.2% |
| Oct 21, 2024 | Robert Burns | H.C. Wainwright | $30.00 | +28.8% |
| Oct 15, 2024 | Matthew Biegler | Oppenheimer | $35.00 | +50.2% |
| Oct 15, 2024 | Derek Archila | Wells Fargo | $32.00 | +37.3% |
| Oct 14, 2024 | Stephen Willey | Stifel Nicolaus | $34.00 | +45.9% |
| Oct 11, 2024 | Roger Song | Jefferies | $41.00 | +76.0% |
| Sep 5, 2024 | Brian Skorney | Robert W. Baird | $26.00 | +11.6% |
| Aug 14, 2024 | Matthew Biegler | Oppenheimer | $27.00 | +15.9% |
| Jun 27, 2024 | Gregory Renza | RBC Capital | $26.00 | +11.6% |
| Jun 18, 2024 | Robert Burns | H.C. Wainwright | $26.00 | +11.6% |
| Jun 5, 2024 | Tyler Van Buren | Piper Sandler | $35.00 | +50.2% |
| Apr 11, 2024 | Gregory Renza | RBC Capital | $23.00 | -1.3% |
Top Analysts Covering NRIX
NRIX vs Sector & Market
| Metric | NRIX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 24 | 8 | 19 |
| Target Upside | +47.3% | +16366.1% | +18.0% |
| P/E Ratio | -6.37 | 3.02 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-08-28 | $12M | $15M | $18M | 10 |
| 2026-08-30 | $5M | $14M | $28M | 5 |
| 2026-11-28 | $7M | $17M | $28M | 8 |
| 2026-11-30 | $50M | $56M | $70M | 13 |
| 2027-02-28 | $6M | $14M | $24M | 8 |
| 2027-05-28 | $7M | $16M | $27M | 8 |
| 2027-05-30 | $7M | $19M | $39M | 5 |
| 2027-08-28 | $7M | $16M | $27M | 8 |
| 2027-08-30 | $8M | $21M | $41M | 5 |
| 2027-11-28 | $7M | $17M | $29M | 8 |
| 2027-11-30 | $37M | $75M | $156M | 12 |
| 2028-11-30 | $131M | $131M | $131M | 12 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-08-28 | $-0.79 | $-0.74 | $-0.70 | 9 |
| 2026-08-30 | $-1.86 | $-0.80 | $-0.15 | 5 |
| 2026-11-28 | $-1.40 | $-0.73 | $-0.19 | 3 |
| 2026-11-30 | $-3.22 | $-2.95 | $-2.59 | 13 |
| 2027-02-28 | $-1.48 | $-0.78 | $-0.20 | 4 |
| 2027-05-28 | $-1.41 | $-0.74 | $-0.19 | 7 |
| 2027-05-30 | $-1.75 | $-0.76 | $-0.14 | 3 |
| 2027-08-28 | $-1.45 | $-0.76 | $-0.20 | 3 |
| 2027-08-30 | $-1.76 | $-0.77 | $-0.14 | 5 |
| 2027-11-28 | $-1.43 | $-0.75 | $-0.19 | 4 |
| 2027-11-30 | $-3.72 | $-2.83 | $-2.13 | 12 |
| 2028-11-30 | $-3.46 | $-2.25 | $-1.25 | 11 |
Frequently Asked Questions
What is the analyst consensus for NRIX?
The consensus among 24 analysts covering Nurix Therapeutics, Inc. (NRIX) is Buy with an average price target of $34.36.
What is the highest price target for NRIX?
The highest price target for NRIX is $41.00, set by Roger Song at Jefferies on 2024-10-11.
What is the lowest price target for NRIX?
The lowest price target for NRIX is $16.00, set by Terence Flynn at Morgan Stanley on 2025-07-15.
How many analysts cover NRIX?
24 analysts have issued ratings for Nurix Therapeutics, Inc. in the past 12 months.
Is NRIX a buy or sell right now?
Based on 24 analyst ratings, NRIX has a consensus rating of Buy (2.00/5) with a +47.3% upside to the consensus target of $34.36.
What are the earnings estimates for NRIX?
Analysts estimate NRIX will report EPS of $-0.74 for the period ending 2026-08-28, with revenue estimated at $15M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.